Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251644 | 0.95 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3255329 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL30932949 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3258035 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3258152 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3251639 | 0.90 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3255601 | 0.90 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3250064 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3254454 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR | |
| SCHEMBL3257418 | 0.85 | DHFR (0.39) | SMN1; SMN2MEN1SLC22A1ALDH1A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651639-B1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2010-05-26 | — | — | EP | claimed |
| US-7524854-B2 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2009-04-28 | — | — | US | claimed |
| US-20060154943-A1 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2006-07-13 | — | — | US | claimed |
| EP-1651639-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | Arpida AG, (CH) | 2006-05-03 | — | — | EP | claimed |
| WO-2005005418-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2005-01-20 | — | — | WO | claimed |
| EP-1651639-B1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-7524854-B2 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20060154943-A1 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2006-07-13 | — | — | US | disclosed |
| EP-1651639-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | Arpida AG, (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005005418-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154943-A1 | Benzofuran derivatives and their use in the treatment of microbial infections | DCXR, NLRP3, NISCH | SMN1; SMN2 3544/4885MEN1 4151/4885SLC22A1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.